接受化疗的老年患者脆弱性评估与管理:ASCO老年肿瘤学实践指南
该指南由ASCO专家小组基于68项研究的系统综述制定,针对≥65岁接受化疗的患者,推荐使用老年评估(GA)识别常规肿瘤评估未捕捉的脆弱性,至少评估功能、合并症、跌倒、抑郁、认知和营养,并依据GA结果制定个体化计划。
要点
- ≥65岁化疗患者应使用GA评估功能、合并症、跌倒、抑郁、认知和营养。
- 推荐CARG或CRASH工具预测化疗毒性风险,Geriatric-8或VES-13预测死亡风险。
- GA结果应指导化疗推荐并用于制定个体化干预计划,需与照护者协作。
核心结论
- 对≥65岁接受化疗的患者,应使用老年评估识别脆弱性并指导个体化治疗决策。
研究设计与样本
- ASCO专家小组基于系统综述制定临床实践指南,共68项研究符合纳入标准作为证据基础。
主要发现
- 证据支持至少评估功能、合并症、跌倒、抑郁、认知和营养。
- 推荐使用CARG或CRASH工具估计化疗毒性风险,Geriatric-8或VES-13预测死亡风险。
关键数值与推荐
- 功能评估采用工具性日常生活活动能力;合并症采用详细病史或验证工具。
- 跌倒采用单一问题筛查;抑郁采用老年抑郁量表;认知采用Mini-Cog或BOMC测试。
- 营养采用非自愿体重减轻评估;非癌性预期寿命≥4年采用ePrognosis验证工具。
临床怎么用
- 临床医生应依据GA结果推荐化疗,并向患者和照护者提供信息以指导决策。
- 应实施针对性的GA指导干预以管理非肿瘤问题,并与照护者协作。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To provide guidance regarding the practical assessment and management of vulnerabilities in older patients undergoing chemotherapy. Methods An Expert Panel was convened to develop clinical practice guideline recommendations based on a systematic review of the medical literature. Results A total of 68 studies met eligibility criteria and form the evidentiary basis for the recommendations. Recommendations In patients ≥ 65 years receiving chemotherapy, geriatric assessment (GA) should be used to identify vulnerabilities that are not routinely captured in oncology assessments. Evidence supports, at a minimum, assessment of function, comorbidity, falls, depression, cognition, and nutrition. The Panel recommends instrumental activities of daily living to assess for function, a thorough history or validated tool to assess comorbidity, a single question for falls, the Geriatric Depression Scale to screen for depression, the Mini-Cog or the Blessed Orientation-Memory-Concentration test to screen for cognitive impairment, and an assessment of unintentional weight loss to evaluate nutrition. Either the CARG (Cancer and Aging Research Group) or CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) tools are recommended to obtain estimates of chemotherapy toxicity risk; the Geriatric-8 or Vulnerable Elders Survey-13 can help to predict mortality. Clinicians should use a validated tool listed at ePrognosis to estimate noncancer-based life expectancy ≥ 4 years. GA results should be applied to develop an integrated and individualized plan that informs cancer management and to identify nononcologic problems amenable to intervention. Collaborating with caregivers is essential to implementing GA-guided interventions. The Panel suggests that clinicians take into account GA results when recommending chemotherapy and that the information be provided to patients and caregivers to guide treatment decision making. Clinicians should implement targeted, GA-guided interventions to manage nononcologic problems. Additional information is available at www.asco.org/supportive-care-guidelines .
引用
- Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018. PMID: 29782209. doi:10.1200/JCO.2018.78.8687
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。